<DOC>
	<DOC>NCT02589236</DOC>
	<brief_summary>This will be a double-blind, randomized, placebo-controlled, parallel group study. The purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with lumacaftor/ivacaftor (Orkambi™).</brief_summary>
	<brief_title>Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation</brief_title>
	<detailed_description>Primary Objective: - Assess the efficacy of N91115 at 12 weeks when added to preexisting treatment with lumacaftor/ivacaftor in adult patients with CF who are homozygous for the F508del-CFTR mutation Secondary Objectives: - Assess the effect of N91115 added to lumacaftor/ivacaftor on safety - Assess the effect of lumacaftor/ivacaftor added to N91115 on the pharmacokinetics of N91115, lumacaftor, and ivacaftor</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Patients must have been treated with lumacaftor/ivacaftor for at least 8 weeks prior to Day 1 (start of dosing) A history of Sweat Chloride (SC) ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) (either before or after starting lumacaftor/ivacaftor treatment) Body weight ≥ 40 kg ppFEV1 40 85 % predicted (inclusive) at screening Oxygen saturation ≥ 90% breathing ambient air at screening Any acute infection that requires treatment or hospitalization within 2 weeks of Study Day 1 Colonization with organisms associated with more rapid decline in pulmonary status, such as Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus Any change in the regimen for chronic therapies for CF lung disease (e.g., Pulmozyme®, hypertonic saline, Azithromycin, TOBI®, Cayston®) within 4 weeks of Study Day 1 Are pregnant, planning a pregnancy, or breastfeeding at screening Blood hemoglobin &lt; 10 g/dL at screening Serum albumin &lt; 2.5 g/dL at screening Abnormal liver function defined as ≥ 3 x upper limit of normal (ULN) History of abnormal renal function within 3 months of screening History of ventricular tachycardia or other clinically significant ventricular arrhythmias History, including the screening assessment, of prolonged QT and/or QTcF (Fridericia's correction) interval History of solid organ or hematological transplantation History of alcohol abuse or drug abuse Ongoing participation in another therapeutic clinical trial Use of continuous (24 hr/day) or nocturnal supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>N91115</keyword>
	<keyword>Cavosonstat</keyword>
</DOC>